Home > Boards > US OTC > Biotechs > NanoLogix, Inc. (NNLX)

NanoLogix PreTest Development Update

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Emerald Isle Member Profile
Followed By 1
Posts 269
Boards Moderated 0
Alias Born 11/06/13
160x600 placeholder
Emerald Isle   Tuesday, 01/14/20 10:51:33 AM
Re: None
Post # of 10036 
NanoLogix PreTest Development Update

NanoLogix is pleased to provide an additional update on the
Screening/Pretest and its potential as a standalone test

An important aspect of the Bacteria and Yeast pretest revealed during Phase One development is the ability to detect and specifically identify Candida yeast infection in human fluids, with no cross-reactivity from other microorganisms. The importance of this is three-fold. The first aspect is that this Candida test is a FIVE-MINUTE TEST. The second is that it can be offered for consumer use in retail outlets, in addition to being used by clinicians for laboratories and medical offices. The third is that there is no other consumer test that specifically identifies Candida, and in doing so, we believe it will provide the ability for consumers to self-diagnose and treat a condition that affects a large percentage of the public.

The previous update from December is provided below for reference

The first phase of Proof of Concept/Principle development work in the UK by a company with Global operations began on October 1st and was completed the first week of December at a cost of roughly $100,000. This phase demonstrated very positive results for Point of Care screening for one specific Candida strain and to very promising results for two bacteria that constitute the primary threats present in Urinary Tract Infections (UTI).

This was a necessary first of four phases that will carry through to patient studies in Houston planned for 2020. The next phase of development will begin in March, after the manufacture and delivery of custom antibodies for the remaining bacteria and Candida.

This schedule will lead to marketing of both the N-Assay and its associated screening pretest for UTI projected for 2021.

The development work on a screening/pretest for seven bacteria and two strains of Candida, though initially focussed upon UTI, will enable NanoLogix to configure the test in a multitude of ways. In doing so, we will have the capability to rapidly and accurately test for possibly up to 15-20 different types of infections, with the ability to determine the specific bacterial cause, the severity of the infection, and the bacteria antibiotic resistance. We anticipate the tests will provide Point of Care and Clinical personnel the ability to dramatically increase both accuracy and speed of diagnosis and in doing so will provide a new weapon in the battle against the development of antibiotic resistance.

The purpose of the Pretest use with the N-Assay is to have a Pretest that will indicate the presence of a specific bacteria within minutes, for which the N-Assay can then be used to rapidly determine both the concentration of the bacteria and its sensitivity to various antibiotics, furnishing Point of Care (POC) personnel the ability to effectively treat the patient with the specific antibiotic required.

In our effort to secure additional funding to reach our goal of $3 million for development, expansion and marketing, we have been in contact with a number of non-NanoLogix-affiliated MDs who have expressed interest in the technology development. Those efforts will continue until we reach our funding requirements.

A PowerPoint presentation on the N-Assay Bacteria Diagnostic is included to illustrate just some of the advantages of the technology. The PowerPoint includes information on upper respiratory infections (URI), general sepsis infections, and sepsis infections related to infant low-birth weights. In future updates there will be information on shares of the diagnostic market devoted to each of those, and other infections for which configurations of the N-Assay are being explored.

A direct link to the PowerPoint is here:


It is also available on our website at: http://nanologix.com/

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
Current Price
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist